Immunocytochemical localisation of caspase-3 in pancreatic islets from type 2 diabetic subjects

Pathology

Volumn 42, Issue 5, 2010, Pages 432-437

  Tomita, Tatsuo ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

Caspase 3; Immunocytochemistry; Pancreatic islets; Type 2 diabetes

Indexed keywords

AMYLOID; BIOLOGICAL MARKER; CASP3 PROTEIN, HUMAN; CASPASE 3;

AGED; APOPTOSIS; CELL COUNT; ENZYMOLOGY; FEMALE; HUMAN; MALE; METABOLISM; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS; PANCREAS ISLET; PATHOLOGY;

AGED; AMYLOID; APOPTOSIS; BIOLOGICAL MARKERS; CASPASE 3; CELL COUNT; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; ISLETS OF LANGERHANS; MALE; MIDDLE AGED; PANCREAS;

EID: 77954791270     PISSN: 00313025     EISSN: 14653931     Source Type: Journal    
DOI: 10.3109/00313025.2010.493863     Document Type: Article

References (29)

1. Martin SJ, Green DR. Protease activation during apoptosis: death by thousand cuts? Cell 1995; 82: 349-352
2. Cohen GM. Caspases: the excursions of apoptosis. Biochem J 1997; 326: 1-16.
3. Hirata H, Takahashi A, Kobayashi S, et al. Caspases are activated in a branched protease cascade and control distinct downstream processes in Fas-induced apoptosis. J Exp Med 1998; 187: 587-600.
4. Tewari M, Quan LT, O'Rourke K, et al. Yama/CPP32ß, a mammalian homolog of CED-3, is a CrmA-inhibitable protease that cleaves the death substrate poly (ADP-ribose) polymerase. Cell 1995; 81: 801-809
5. Gown AM, Willingham MC. Improved detection of apoptotic cells in archival paraffin sections: Immunohistochemistry using antibodies to cleaved caspase 3. J Histochem Cytochem 2002; 50: 449-454
6. Cell Signaling Technology. Cleaved Caspase-3 (Asp 175) Antibody. Publication #9661. Beverly, MA: Cell Signaling Technology, 2006; 1-7.
7. Butler AE, Jansen J, Bonner-Weir S, et al. β-cell deficit and increased β-cell apoptosis in humans with type 2 diabetes. Diabetes 2003; 52: 102-110
8. Cnop M, Welsh N, Jonas JC, et al. Mechanisms of pancreatic-β cell death in type 1 and type 2 diabetes. Diabetes 2005; 54: s97-107.
9. Tomita T, Iwata K. Gelatinases and inhibitors of gelatinases in pancreatic islets and islet cell tumors. Mod Pathol 1997; 10: 47-54.
10. Tomita T. Metallothionein in pancreatic endocrine tumors. Mod Pathol 2000; 13: 389-395
11. Tomita T. Immunocytochemical localization of caspase-3 for pancreatic islets from type 1 diabetic subjects. Islets (in press).
12. Tomita T. Caspase-3 immunocytochemical staining for pancreatic endocrine tumors. Hum Pathol 2009; 40: 1050-1052
13. Milliga CE, Prevette D, Yagimura H, et al. Peptide inhibitors of the ICE proteinase family arrest programmed cell death of motor neurons in vivo and in vitro. Neuron 1995; 15: 385-393
14. Enari M, Talanian RV, Wong WW, Nagata S. Sequential activation of ICE-like and CPP32-like proteinases during Fas-mediated apoptosis. Nature 1996; 380: 723-726
15. Yamada K, Ichikawa F, Ishikawa-Shigemoto S, et al. Essential role of caspase-3 in apoptosis of mouse b cells transfected with human Fas. Diabetes 1999; 48: 478-483
16. Marchetti P, DelGuerra S, Marselli L, et al. Pancreatic islets from type 2 diabetic patients have functional defects and increased apoptosis that are ameliorated by Metform. J Clin Endocrinol Metab 2004; 89: 5535-5541
17. Tomita T. New markers for pancreatic islets and islet cell tumors. Pathol Int 2002; 52: 425-432
18. Tomita T. Amylin in pancreatic islets and pancreatic endocrine neoplasms. Pathol Int 2003; 53: 591-595
19. Birdal-Hansen T, Moore WGI, Bodden MK, et al. Matrix metalloproteinases - Review. Crit Rev Oral Biol 1993; 4: 197-250.
20. Perez SE, Cano DA, Dao-Pick T, et al. Matrix metalloproteinases 2 and 9 are dispensable for pancreatic islet formation and function in vivo. Diabetes 2005; 54: 694-701.
21. Westermark P, Wernstedt C, Wilander E, Slettern K. A novel peptide in the calcitonin gene-related peptide family as amyloid fibril in the endocrine pancreas. Biochem Bioph Res Commun 1986; 140: 827-831
22. Jansen J, Ashley RH, Harrison D, McIntyre R, Butler PC. The mechanism of islet amyloid polypeptide toxicity is membrane disruption by intermediate sized toxic amyloid particles. Diabetes 1999; 8: 491-498
23. Zhang S, Lie J, Dragnunow M, Cooper GSJ. Fibrillogenic amylin evokes islet beta-cell apoptosis through linked activation of a cascade and JNK1. J Biol Chem 2003; 278: 52810-52819
24. Kloppel G. Islet histopathology in diabetes mellitus. In: Kloppel G, Heinz P, editors. Pancreatic Pathology. Edinburgh: Churchill Livingstone, 1984; 154-192
25. Westermark P, Wilander E. The influence of amyloid deposits on the islet volume in maturity onset diabetes mellitus. Diabetologia 1978; 15: 417-421
26. Hoppener JWM, Ahren B. Islet amyloid and type 2 diabetes mellitus. N Eng J Med 2000; 343: 411-419
27. Laakso M, Lehto S. Epidemiology of macrovascular heart disease in diabetes. Diabetes Rev 1997; 5: 294-315.
28. National Institutes of Health. Kidney Disease of Diabetes. NIH Publication No. 3925. Bethesda, MD: NIH, 1995.
29. Tomita T. Cleaved caspase-3 immunocytochemical staining for pancreatic islets and pancreatic endocrine tumors: A potential marker for biological malignancy. Islets 2010; 2: 82-88